Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer

Abstract

Aim: This study reports the outcomes of cytoreductive prostate cryoablation and metronomic cyclophosphamide for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Methods: Patients with mHSPC from the authors' prostate cancer database who had received cytoreductive prostate cryoablation and metronomic cyclophosphamide were identified retrospectively. Results: Eight consecutive patients were enrolled in the study. All the patients tolerated combination therapy. The median metastatic castration-resistant prostate cancer-free survival was 62.5 months. Seven patients (87.5%) had a prostate-specific antigen nadir <0.1 ng/ml. Dysuria and hematuria before prostate cryoablation disappeared within 1 month after cryosurgery, and no incontinence was seen after prostate cryoablation. No local therapy was needed during follow-up. Conclusion: Cytoreductive prostate cryoablation and metronomic cyclophosphamide prove an effective and safe combination therapy for mHSPC.

Biosynthesis of silver nanoparticles using Pterorhachis zenkeri: Characterization and evaluation of antioxidant, anti-apoptotic, and androgenic properties in TM3 Leydig cells exposed to cyclophosphamide

“…Cyclophosphamide (CP) is an anticancer drug widely used in the treatment of various cancers including breast cancer (Kimura et al 2021), prostate cancer (Li et al 2022) and ovarian cancer (Handolias et al 2016), but its chronic use can cause severe damages to normal living cells (El-Emam 2021, Barberino et al 2023). After administration, CP is transformed into its active metabolites phosphoramide mustard (responsible for its antineoplastic potential) and acrolein (toxic metabolite of CP) with the action of cytochrome P450 mixed functional oxidase system (Zhang et al 2005).…”

Cryoablation for nonmetastatic castration resistant prostate cancer: feasibility, safety, quality of life and oncological outcomes

“…Cryoablation is one type of local treatments and increasingly used with the advantages of minimal invasiveness, rapid recovery and de nite e cacy and has obtained excellent e cacy for localized or metastatic PCa [10,11]. We hypothesized that it may be effective for nonmetastatic CRPC because of its mechanisms of local tumor killing and activation of systemic immune response [12].…”